The effects of clofazimine on neutrophil activities such as random motility, migration to the leukoattractants endotoxin-activated serum and N-formyl-Lmethionyl-L-leucyl-L-phenylalanine phagocytosis of Candida albicans, postphagocytic hexose-monophosphate shunt activity, and myeloperoxidase-mediated iodination and the effects of clofazimine on lymphocyte transformation to mitogens were assessed in vitro and after ingestion of the drug by normal individuals and patients with lepromatous leprosy. For in vitro studies, the concentration range of the drug investigated was 10-6 M to 10-2 M. For in vivo studies, subjects ingested 200 mg of clofazimine daily for a period of 5 days. At concentrations of 5 x 10-6 M to 5 x 10-3 M clofazimine caused a progressive dose-dependent inhibition of neutrophil motility without detectable effects on phagocytosis, postphagocytic hexose-monophosphate shunt activity, or myeloperoxidase-mediated iodination. Over the same concentration range, clofazimine inhibited lymphocyte transformation. The inhibitory effect on neutrophil motility was associated with a spontaneous stimulation of oxidative metabolism and could be prevented by coincubation of dapsone with clofazimine. After ingestion of clofazimine responsiveness of lymphocytes to mitogens was decreased in normal volunteers and leprosy patients; neutrophil motility in normal individuals was likewise inhibited.
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Clofazimine (5) , also known as B663 or Lamprene, is an extensively used anti-leprosy drug. Apart from its anti-mycobacterial activity, clofazimine has also been reported to possess antiinflammatory activity (17) . This property enhances the value of clofazimine in leprosy, since it may also be used to control adverse immunological reactions. In this study, we have investigated the effects of clofazimine in vitro and in vivo on the motility, phagocytosis, and postphagocytic metabolic activities of neutrophils and transformation to mitogens of lymphocytes from normal individuals and patients with lepromatous leprosy. The effects of combinations of clofazimine and dapsone on the motility of neutrophils from patients with leprosy have also been investigated.
MATERIALS AND METHODS Chemotherapeutic agents. Clofazimine in 100-mg capsules of pure drug was obtained from Ciba-Geigy, Johannesburg. For in vitro studies, the drug was solubilized in dimethyl sulfoxide (DMSO) to give a concentration range of 106 M to 10-3 M (equivalent to 0.3 to 300 j.Lg/ml) in Hanks balanced salt solution (HBSS) for studies of motility, 0.15 M phosphatebuffered saline for phagocytic studies and TC199 for lymphocyte studies. Both HBSS and TC199 were obtained from GIBCO Laboratories, Grand Island, N.Y. Control systems were included for each clofazimine concentration investigated, and these contained the corresponding DMSO concentrations: 0.0015 to 1.5% DMSO for 10-6 M to 10-3 M clofazimine.
Dapsone, obtained from Lennon Ltd., Port Elizabeth, South Africa, was used at concentrations previously found to increase neutrophil motility in vitro (3).
Leprosy patients. We used 12 newly admitted untreated patients in this study (two patients with borderline-tuberculoid leprosy, two with borderline leprosy, six with borderline-lepromatous leprosy, and two with lepromatous leprosy). Only patients with borderlinelepromatous leprosy and -lepromatous leprosy were used for the in vivo studies; this group comprised five patients with borderline-lepromatous leprosy and one patient with lepromatous leprosy. The group used for in vitro studies comprised two patients with borderline-tuberculoid leprosy, two with borderline leprosy, and two with lepromatous leprosy. The classification was based on the clinical and histopathological criteria of Ridley and Jopling (12) .
For in vivo studies, six normal adult volunteers and six newly diagnosed patients with lepromatous leprosy ingested 200-mg capsules of clofazimine as one oral daily dose for 5 days. Tests of neutrophil motility and lymphocyte transformation were performed before the ingestion of clofazimine, at 2 and 24 h after the ingestion of one oral dose of 200 mg of clofazimine, and on day 5 of ingestion of 200 mg of clofazimine daily (testing was performed 2 h after ingestion of the last dose).
Neutrophil motility. Neutrophils, obtained from heparinized venous blood (5 U of heparin per ml) from normal adult volunteers, were suspended in a final concentration of 3 x 106 to 5 x 106/ml in HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid, Sigma Chemical Co., St. Louis, Mo.)-buffered HBSS after hypotonic lysis of residual erythrocytes with 0.84% ammonium chloride as previously described (4) . The leukoattractants used were endotoxin-activated fresh autologous serum (EAS) and the synthetic leukotactic tripeptide N-formyl-L-methionyl-L-leucyl-Lphenylalanine (Miles Laboratories Inc., Elkhart, Ind.). Bacterial endotoxin (100 ,ug) (Escherichia coli 0127:B8, Difco Laboratories, Detroit, Mich.) was added to I ml of serum, and the mixture was diluted eightfold with HBSS. N-Formyl-L-methionyl-L-leucyl-L-phenylalanine was used at a final concentration of 5 x l0' M in HBSS supplemented with 0.1% bovine serum albumin.
In random migration studies the leukoattractant was replaced with an equal volume of bovine serum albumin-supplemented HBSS. Assays of motility were performed in modified Boyden chambers by using 5- p.m pore size membrane filters (Sartorius-membranfilter, Gottingen, West Germany) and a 2-h incubation period. Clofazimine together with the neutrophils was introduced into the upper compartment of the Boyden chamber. The combined effects of clofazimine and dapsone on neutrophil motility were investigated by using a constant concentration of 10'-M clofazimine.
Dapsone, which has previously been shown to stimulate neutrophil motility (3), was used at concentrations of 1 x 10-3 M, 2.5 x 10-3 M, and 5 x 10-3 M.
Phagocytic studies. Pure neutrophil suspensions in phosphate-buffered saline were prepared as previously described (4) . Phagocytosis of Candida albicans was performed with a neutrophil/C. albicans ratio of 1:3 (4) . Various concentrations of clofazimine were added in 0.1-ml volumes to give a final reaction volume of 1 ml. The results are expressed as the percentage of C. albicans ingested after incubation periods of 10 (4, 19) . The reaction mixture of 1 ml contained 2 x 106 neutrophils, 0.1 ml of autologous serum, 107 C. Co.) in a reaction volume of 1 ml. Control systems contained no clofazimine. Tubes were incubated for 30 min at 37°C before the addition of luminol and then for 60 min more. Spontaneous chemiluminescence was measured at 10-min intervals on a Lumac Biocounter (model 2010, Lumac Systems Inc., Titusville, Fla.). The emitted light was measured and recorded as counts per minute.
Myeloperoxidase-mediated iodination of C. albicans. Myeloperoxidase-mediated iodination of C. albicans was determined by a modified method of Root and Stossel (4, 13). To 0.1 ml of neutrophil suspension (107/ ml) were added 0.1 ml of C. albicans (108/ml), 0.1 ml of fresh autologous serum, 0.1 ml of the appropriate drug concentration, 0.1 ml of a 125I-labeled solution (0.6 ,uCi/ml, sodium iodate, New England Nuclear Corp.) and 0. Table 2 . Similar but less striking effects were observed in patients with leprosy after ingestion of clofazimine (Table 5) .
DISCUSSION
Clofazimine at concentrations of >10-6 M has been found to inhibit neutrophil motility and lymphocyte transformation in vitro. These activities of the drug may be related to its reported anti-inflammatory properties (9, 11, 14, 17) . Clofazimine, which increases phagocytosis by mac- with lepromatous leprosy (7, 15, 18) and improves with dapsone therapy as does lymphocyte transformation (1, 2) . In patients with leprosy, antimicrobial therapy with dapsone may improve cellular immunity with an increased probability of occurrence of adverse immunological reactions. Therapy with clofazimine, which inhibits cellular immune functions, should be accompanied by fewer such reactions and may be useful in providing good antimicrobial therapy together with a measure of control of harmful immunological reactions. Studies on the combined effects of clofazimine and dapsone on neutrophil migration in vitro suggest that clapsone may nullify the anti-inflammatory effects of clofazimine. Combinations of dapsone and clofazimine may therefore not be compatible in the chemotherapy of leprosy patients with adverse immunological reactions such as erythema nodosum leprosum. This possibility should be investigated in patients with erythema nodosum leprosum, but must not be confused with the beneficial effects of clofazimine-dapsone combinations for leprosy caused by drug-resistant Mycobacterium leprae.
